# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 531-540 of 561 results.
A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome
Status: Not yet recruiting
Last Changed: Apr 02, 2019
First Received: Apr 02, 2019
Disease(s): Richter Syndrome
Intervention(s): Acalabrutinib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Rituximab
Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL
Status: Recruiting
Last Changed: Jul 22, 2020
First Received: Sep 11, 2018
Disease(s): Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
Intervention(s): PBCAR0191, Fludarabine, Cyclophosphamide
Locations: City of Hope, Duarte, California, United States
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
Indiana Blood and Marrow, Indianapolis, Indiana, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
... and 2 other locations.
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
Status: Recruiting
Last Changed: Apr 22, 2020
First Received: Mar 17, 2017
Disease(s): Advanced Solid Tumors, Cancer, Hematologic Malignancies
Intervention(s): ABBV-621, Venetoclax, Bevacizumab, FOLFIRI
Locations: Yale University /ID# 158029, New Haven, Connecticut, United States
University of Chicago /ID# 158030, Chicago, Illinois, United States
Ingalls Memorial Hosp /ID# 171221, Harvey, Illinois, United States
Illinois Cancer Care, PC /ID# 214998, Peoria, Illinois, United States
Univ Michigan Med Ctr /ID# 207134, Ann Arbor, Michigan, United States
... and 16 other locations.
A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
Status: Recruiting
Last Changed: Jun 25, 2019
First Received: Jan 29, 2015
Disease(s): Leukemia, Lymphoma
Intervention(s): Chimeric Antigen Receptor Modified T cells Targeting CD19
Locations: Southwest Hospital of Third Millitary Medical University, Chongqing, Chongqing, China
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic
Status: Recruiting
Last Changed: Jun 18, 2020
First Received: Dec 09, 2016
Disease(s): Hematologic Malignancies
Intervention(s): Haplo HCT <55 years old, Haplo HCT ≥55 years old, GVHD Prophylaxis, Haplo HCT ≥55 and < 65 years old, Haplo HCT ≥65 and ≤75 years old
Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Recruiting
Last Changed: Jul 17, 2020
First Received: Dec 27, 2017
Disease(s): Precursor Cell Lymphoblastic Leukemia-Lymphoma
Intervention(s): Daratumumab, Vincristine, Prednisone, Doxorubicin, Peg-asparaginase, Cyclophosphamide, Cytarabine, 6-mercaptopurine, Methotrexate
Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States
Phoenix Children's Hospital, Phoenix, Arizona, United States
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
Children's Hospital Orange County, Orange, California, United States
Stanford University, Palo Alto, California, United States
... and 52 other locations.
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
Status: Recruiting
Last Changed: Jul 08, 2020
First Received: Mar 23, 2017
Disease(s): B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
Intervention(s): Cirmtuzumab, Ibrutinib, Cirmtuzumab plus ibrutinib
Locations: City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States
UCSD Moores Cancer Center, La Jolla, California, United States
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
Yale Cancer Center, New Haven, Connecticut, United States
Lousiana State University Health New Orleans (NCI Community Oncology Research Program), New Orleans, Louisiana, United States
... and 8 other locations.
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Status: Recruiting
Last Changed: Jun 02, 2020
First Received: Nov 06, 2017
Disease(s): Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
Intervention(s): JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib
Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
City of Hope, Duarte, California, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
University of California, Los Angeles, Los Angeles, California, United States
... and 30 other locations.
A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice
Status: Recruiting
Last Changed: Jan 13, 2020
First Received: Feb 07, 2018
Disease(s): Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell
Intervention(s): Ibrutinib
Locations: DUMMY, Dummy, France
A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
Status: Recruiting
Last Changed: May 29, 2020
First Received: Jun 16, 2017
Disease(s): Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell
Intervention(s): Ibrutinib 420 mg, Ibrutinib 560 mg
Locations: Vedanta Institute of Medical Science, Ahmedabad, India
Avron Hospitals Pvt. Ltd, Ahmedabad, India
Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, India
Basavatarakam Indo-American Hospital, Hyderabad, India
Bhagwan Mahaveer Cancer Hospital & Research Centre, Jaipur, India
... and 9 other locations.